Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has provided an announcement.
Cyclopharm Limited has applied for quotation on the ASX of 5,263,158 ordinary fully paid shares, with an issue date of 20 April 2026. The new securities, issued under previously announced transactions, will expand the company’s listed share capital and may enhance its liquidity and visibility among investors.
The application formalises the admission of these additional shares to trading on the exchange, aligning Cyclopharm’s capital structure with earlier market disclosures. The move could support future capital-raising flexibility and signals continued engagement with the ASX market for funding and growth initiatives.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australia-based company listed on the ASX under the code CYC. It operates in the healthcare sector and issues ordinary fully paid shares as its primary equity securities for investors in the Australian capital markets.
Average Trading Volume: 145,437
Technical Sentiment Signal: Sell
Current Market Cap: A$93.62M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.